Jump To Section
Featured Stories
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
GSK Ends Tough Week With Ulcerative Colitis Therapy Termination
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.
Servier and MiNA Target Neurodegenerative Disease With Novel RNA Therapy
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
Coronavirus Spotlight
J&J Has A Plan B If Gamechanger Single Dose Vaccine Disappoints
If J&J’s gamble on a single dose pays off, it could rapidly advance the fight against SARS-CoV2 – but a second study will provide a safety net.
Rolling Coverage Of The Coronavirus Outbreak And The Biopharma Industry's Response Is Here.
Latest News
Recent Tweets from Scrip
Infographics
The Race To Vaccinate The World Against COVID-19
Our graphic tracker of key developments from emergency authorized vaccines, the global roll-out, and late-stage vaccine candidates.
Infographic: Cancer Deal-Making In 2020
Despite the COVID-19 pandemic, 2020 has seen a hectic pace of cancer deal-making, including the two largest biopharma M&A deals of the year and 23 with upfront value of at least $100m.
The Top 10 Best-Selling Drugs of 2019
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Commercial Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
ViiV Anticipates 10%-15% Switchover To Long-Term HIV Option Cabenuva
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
Biocon Biologics CEO Makes Surprise Exit
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
Fire At Serum Institute Won't Disrupt AZ-Oxford COVID-19 Vaccine Supplies
Set to provide a COVID-19 vaccine partnered with AstraZeneca/Oxford to COVAX and various governments from Brazil to South Africa, India's Serum Institute assures that a fire at one of its units under construction will not impact supplies.
Prices Plunge As Xarelto Generics Arrive In India
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
As Seagen Matures, CEO Siegall Talks About Moving The Growth Goalposts
The ADC specialist could have a fourth cancer drug on the market this year and is preparing for its first commercial launch in Europe.
Lilly COVID-19 Antibody Has Role As Stopgap When Too Late To Vaccinate
The company will seek emergency use authorization to prevent outbreaks in nursing homes. Regeneron is also positioning its antibody cocktail to prevent infections.
Policy & Regulation Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Valneva Starts COVID-19 Vaccine Production In Scotland
Valneva is scaling up manufacture of its coronavirus vaccine alongside the clinical development program, with a view to meeting its commitment to provide millions of doses for use in the UK and the EU.
FDA Approval Opens Up Gastric Cancer To Daiichi Sankyo/AZ’s Enhertu
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This selection of recent insights from our experienced on-the-ground team will help.
Research & Development Explore this Topic
Remove Alert
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Pipeline Watch: Phase III Starts In Hypertension, Atopic Dermatitis
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements
ConserV Bioscience: Getting Ahead Of New COVID-19 Strains
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
RedHill Could Soon Seek EUA For COVID-19 Therapy
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.